Boston Scientific’s new CEO takes the reins

Michael Mahoney

Boston Scientific (NYSE:BSX) officially handed the corner office over to Michael Mahoney today, marking the end of a year-long "transition period" for the new CEO.

The day came without fanfare for the medical device company, with a veritable media freeze on the new head man as he embarks on what is likely to be a busy 1st day at the helm.

Mahoney, 47, has spent just over a year at Boston Scientific as president, after being recruited from rival device maker Johnson & Johnson‘s (NYSE:JNJ) diagnostics and devices group.

Late last year Boston Scientific announced Mahoney as the successor to former CEO J. Raymond Elliott, who manned the corner office for 2 years before announcing his retirement in May 2011. Elliott officially retired in October 2011, the day Mahoney joined the company.

"Really, the opportunity was too good to pass up," Mahoney told MassDevice.com about the decision to accept the job at Boston Scientific.

He left behind a promising career and good friends, but the chance to effect a turnaround at a top-tier device maker was too appealing, he told an audience at MassDevice.com’s Big 100 Roundtable East event in Waltham, Mass., last July.

Boston Scientific’s Mike Mahoney on leaving JNJ

Mahoney’s appointment came with some strings attached – he was unable to immediately take over as CEO due to J&J’s enforcement of a non-competition agreement.

The deal required that Mahoney’s duties as president exclude business lines that compete with J&J, including divisions that accounted for about 57% of BSX’s revenues last year, analysts said.

Hank Kucheman, who was the executive vice president and group president of the cardiology, rhythm and vascular group, stepped up to serve as interim CEO until Mahoney could assume the role. Kucheman has been driving the ship since October 2011, but Mahoney has played a prominent role, speaking at industry conferences and during earnings calls.

"Mike and I have worked closely and very effectively together in our respective roles over this past year," Kucheman said in the company’s most recent quarterly earnings call. "Mike Mahoney is the right leader at the right time to return BSC to its rightful place in the medical device marketplace, period."

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply